Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177- CC49

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1491-1496

  Meredith, Ruby F ^a   Partridge, Edward E ^b   Alvarez, Ronald D ^b   Khazaeli, M B ^b   Plott, Gene ^b   Russell, Charles D ^b   Wheeler, Richard H ^b   Liu, Tiepu ^b   Grizzle, William E ^b   Schlom, Jeffrey ^b   LoBuglio, Albert F ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

lutetium 177 CC49; ovarian cancer; radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; LUTETIUM 177; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC49 LU 177; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; IMMUNOSCINTIGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ADENOCARCINOMA; AGED; ANTIBODIES, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUTETIUM; MIDDLE AGED; OVARIAN NEOPLASMS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 10144262627     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Venesmaa P. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990. Obstet Gynecol 1994;84:8-11.
2. Epenetos A, Munro A, Stewart S, et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987;5(12):1890-1899.
3. Fein D, Morgan L, Marcus R, et al. An analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage. Int J Radiat Oncol Biol Phys 1994;29:169-176.
4. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993;68:403-406.
5. 90Y with and without EDTA in ovarian cancer. Proc Adv Innovative Oncol: Biomodulation, Chemoimmunotherapy and Selected Phase II Drugs 1991:38-40.
6. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992;10:1485-1491.
7. Markman M, Reichman B, Hakes T, et al. Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 1993;71(4):S1565-S1570.
8. Muto M, Finkler N, Kassis A, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gyn Oncol 1992;45:265-272.
9. Piver M, Recio F, Baker T, Driscoll D. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer 1994;73:1693-1698.
10. Salk D, Lesley T, Wiseman G, et al. A phase I clinical trial of a fractionated dose intraperitoneal administration of rhenium-186 monoclonal antibodies in ovarian cancer [Abstract]. Antib Immunoconj Radiopharm 1992;5:359.
11. 90Y-labeled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer 1988;3:S71-S76.
12. 131I-labeled B72.3 monoclonal antibody. Radiology 1988; 167:35-40.
13. Larson S, Carrasquillo J, Colcher D, et al. Estimates of radiation absorbed dose for intraperitoreally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med 1991;32:1661-1667.
14. Chatal J, Saccavini J, Gestin J, et al. Biodistribution of indium-111-labeled OC125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res 1989;49:3087-3094.
15. Colcher D, Esteban J, Carrasquillo J. Complementation of intracavitary and intravenous administration of a monoclonal antibody B72.3 in patients with carcinoma. Cancer Res 1987;47:4218-4224.
16. Ward B, Mather S, Hawkins L, et al. Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. Cancer Res 1987;47:4719-4723.
17. 177Lu-labeled immunoconjugate. Cancer Res 1991;51:2889-2896.
18. Schlom J, Colcher D, Siler K, et al. Tumor targeting with monoclonal antibody B72.3: experimental and clinical results. In: Goldenberg D, ed. Cancer imaging with radiolabeled antibodies. Boston, MA: Kluwer Academic Publishing, 1990:313-335.
19. Divgi C, Scott A, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colorectal carcinoma. J Nucl Med 1995;36:586-592.
20. Meredith R, Bueschen A, Khazaeli M, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-1022.
21. 131-CC49 murine MAB plus alpha interferon in refractory breast cancer [Abstract]. Antib Immunoconj Radiopharm 1994;7:84.
22. Schlom J, Eggensperger D, Colcher D, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992;52:1067-1072.
23. Mulligan T, Carrasquillo J, Chung Y, et al. Phase I study of intravenous lutetium-177-labeled CC49 monoclonal antibody in patients with advanced adenocarcinoma [Abstract]. Proc Am Soc Clin Oncol 1993;12:293.
24. Levinger R and Berman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No. 1, revised. New York, NY: Society of Nuclear Medicine, 1976.
25. Siegel J, Wessels B, Watson E, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3:213-233.
26. Sgouros G. Bone Marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-694.
27. Stabin M. MIRDOSE - the personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996: in press.
28. Labaune JP. Handbook of pharmacokinetics, toxicity assessment of chemicals. New York, NY: Wiley and Sons Publishing; 1989.
29. Liu T. Characteristics of pharmacokinetical modeling in phase I clinical trial of radiolabeled monoclonal antibody chimeric B72.3. Controlled Clin Trials 1991;12: 654-655.
30. 177Lu-CC49 monoclonal antibody in patients with recurrent or persistent ovarian cancer [Abstract]. Advances in the application of monoclonal antibody in clinical oncology. 11th International Hammersmith Conference, Molyvos, Lesvos, Greece, May 23-26, 1994.
31. Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer: a 10-year experience. Cancer 1985;55:2285-2290.
32. Martinez A, Schray M, Howes AE, Bagshaw MA. Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24-year experience. J Clin Oncol 1985;3:901-911.
33. Wheeler R, Meredith R, Saleh M, et al. A phase II trial of IL-1 + radioimmunotherapy in patients with metastatic colon cancer [Abstract]. Proc Am Soc Clin Oncol 1994;13:295.
34. 131I-chimeric B72.3 antibody therapy. Antibod Immunoconj Radiopharm 1993;6:39-46.